Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Gynecologic 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 1228Lung Neoplasms 560Colorectal Neoplasms 282Breast Neoplasms 257Neoplasms 254Melanoma 236Small Cell Lung Carcinoma 234Ovarian Neoplasms 234Pancreatic Neoplasms 186Squamous Cell Carcinoma of Head and Neck 171Neoplasm Metastasis 171Carcinoma, Renal Cell 164Stomach Neoplasms 158Triple Negative Breast Neoplasms 127Head and Neck Neoplasms 121Esophageal Neoplasms 115Prostatic Neoplasms 106Urinary Bladder Neoplasms 105Colonic Neoplasms 95Uterine Cervical Neoplasms 93Endometrial Neoplasms 93Mesothelioma 84Mesothelioma, Malignant 79Carcinoma, Hepatocellular 78Sarcoma 70Carcinoma, Transitional Cell 69Kidney Neoplasms 65Carcinoma, Ovarian Epithelial 50Adenocarcinoma of Lung 47Rectal Neoplasms 45

Interventions

Theophylline 1Loperamide 1Fecal Microbiota Transplantation 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Diarrhea × Thoracic × Clear all
NCT04038619 2026-03-20

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Recruiting
40 enrolled
BreastDermatologicGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colitis, Diarrhea, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Urogenital Neoplasms, Uterine Neoplasms

NCT02080078 2019-05-03

A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline

AHS Cancer Control Alberta

Phase 1 Terminated
15 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Diarrhea

Data powered by HemOnc (CC BY 4.0) Colophon âš¡